Which is better, the Lao version or the Indian version of giritinib?

The Laos version and the Indian version of Gilteritinib both belong to the production category of Gilteritinib generic drugs and are produced by different manufacturers. The ingredients of the drugs they produce are basically the same as those of the original Gilteritinib drug. The difference may lie in different prices and different specifications. It is understood that there are generic drugs produced by Laos Lucius and Daxiong Pharmaceuticals on the market, but there are no Indian versions of generic drugs yet. There may be original drugs on the market in India. The price of a common specification of 40mg*84 tablets per box is over RMB 4,000 (the price may fluctuate due to exchange rates).

Giritinib is a targeted drug. Its mechanism of action is to interfere with abnormal signaling pathways in leukemia cells by inhibiting the activity of FLT3 receptor tyrosine kinase. The FLT3 receptor tyrosine kinase regulates cell growth and differentiation in normal cells, but in patients with FLT3 mutation-positive acute myeloid leukemia (AML), the FLT3 gene is mutated, leading to abnormal activation of the FLT3 receptor and promoting abnormal proliferation and growth of leukemia cells. Therefore, it is considered a targeted therapy that acts more specifically on leukemia cells without having a significant effect on normal cells.

The original drug of geritinib has been launched in China, but it has not yet been included in the medical insurance. The price of each box of 40mg*42 tablets may be more than 20,000 yuan. The price of the Hong Kong version of the original drug is about 90,000 yuan per box. The price of the European version of the original drug, 40mg*84 tablets, per box listed overseas is around RMB 210,000 (the price may fluctuate due to exchange rates), which is very expensive. For more overseas drug information and specific prices, please consult Yaode Medical Consultant.